Thermo Fisher introduces MagMax Sequential DNA/RNA kit to advance blood cancer research

US-based Thermo Fisher Scientific has introduced the Applied Biosystems MagMAX Sequential DNA/RNA kit to enable clinical and translational researchers to conduct comprehensive DNA and RNA genomic analysis and streamline detection of genetic abnormalities found in hematological malignancies.

The MagMAX Sequential DNA/RNA kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications. This integration merges two separate workflows into one sequential process, accommodating up to 15,000 white blood cells per microliter without the need for an additional red blood cell lysis step. By simplifying the workflow and reducing the need for multiple processes, it enhances overall lab productivity and helps reduce costs.

Research and clinical applications of hematological cancer like leukemia, lymphoma and myeloma is increasingly important, as approximately 10% of new cancer cases each year are hematological, according to the Leukemia & Lymphoma Society. To understand and identify the cancer-causing genetic alterations that cause hematological cancer, researchers need to be able to efficiently isolate nucleic acids from hematological samples.

The product is designed for specialty labs, large health system labs, academic medical centers and pharmaceutical and biotechnology companies developing clinical research in personalized medicine, conducting internal development, clinical research or clinical trials.